Cargando…
Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
High serum levels of free fatty acids (FFAs) could contribute to obesity-induced nephropathy. CD36, a class B scavenger receptor, is a major receptor mediating FFA uptake in renal proximal tubular cells. Empagliflozin, a new anti-diabetic agent, is a specific inhibitor of sodium-glucose co-transport...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621539/ https://www.ncbi.nlm.nih.gov/pubmed/34830289 http://dx.doi.org/10.3390/ijms222212408 |
_version_ | 1784605482881646592 |
---|---|
author | Huang, Chiang-Chi Chou, Chia-An Chen, Wei-Yu Yang, Jenq-Lin Lee, Wen-Chin Chen, Jin-Bor Lee, Chien-Te Li, Lung-Chih |
author_facet | Huang, Chiang-Chi Chou, Chia-An Chen, Wei-Yu Yang, Jenq-Lin Lee, Wen-Chin Chen, Jin-Bor Lee, Chien-Te Li, Lung-Chih |
author_sort | Huang, Chiang-Chi |
collection | PubMed |
description | High serum levels of free fatty acids (FFAs) could contribute to obesity-induced nephropathy. CD36, a class B scavenger receptor, is a major receptor mediating FFA uptake in renal proximal tubular cells. Empagliflozin, a new anti-diabetic agent, is a specific inhibitor of sodium-glucose co-transporter 2 channels presented on renal proximal tubular cells and inhibits glucose reabsorption. In addition, empagliflozin has shown renoprotective effects. However, the mechanism through which empagliflozin regulates CD36 expression and attenuates FFA-induced lipotoxicity remains unclear. Herein, we aimed to elucidate the crosstalk between empagliflozin and CD36 in FFA-induced renal injury. C57BL/6 mice fed a high-fat diet (HFD) and palmitic acid-treated HK-2 renal tubular cells were used for in vivo and in vitro assessments. Empagliflozin attenuated HFD-induced body weight gain, insulin resistance, and inflammation in mice. In HFD-fed mice, CD36 was upregulated in the tubular area of the kidney, whereas empagliflozin attenuated CD36 expression. Furthermore, empagliflozin downregulated the expression of peroxisome proliferator-activated receptor (PPAR)-γ. Treatment with a PPARγ inhibitor (GW9662) did not further decrease PPARγ expression, whereas a PPARγ antagonist reversed this effect; this suggested that empagliflozin may, at least partly, decrease CD36 by modulating PPARγ. In conclusion, empagliflozin can ameliorate FFA-induced renal tubular injury via the PPARγ/CD36 pathway. |
format | Online Article Text |
id | pubmed-8621539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86215392021-11-27 Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice Huang, Chiang-Chi Chou, Chia-An Chen, Wei-Yu Yang, Jenq-Lin Lee, Wen-Chin Chen, Jin-Bor Lee, Chien-Te Li, Lung-Chih Int J Mol Sci Article High serum levels of free fatty acids (FFAs) could contribute to obesity-induced nephropathy. CD36, a class B scavenger receptor, is a major receptor mediating FFA uptake in renal proximal tubular cells. Empagliflozin, a new anti-diabetic agent, is a specific inhibitor of sodium-glucose co-transporter 2 channels presented on renal proximal tubular cells and inhibits glucose reabsorption. In addition, empagliflozin has shown renoprotective effects. However, the mechanism through which empagliflozin regulates CD36 expression and attenuates FFA-induced lipotoxicity remains unclear. Herein, we aimed to elucidate the crosstalk between empagliflozin and CD36 in FFA-induced renal injury. C57BL/6 mice fed a high-fat diet (HFD) and palmitic acid-treated HK-2 renal tubular cells were used for in vivo and in vitro assessments. Empagliflozin attenuated HFD-induced body weight gain, insulin resistance, and inflammation in mice. In HFD-fed mice, CD36 was upregulated in the tubular area of the kidney, whereas empagliflozin attenuated CD36 expression. Furthermore, empagliflozin downregulated the expression of peroxisome proliferator-activated receptor (PPAR)-γ. Treatment with a PPARγ inhibitor (GW9662) did not further decrease PPARγ expression, whereas a PPARγ antagonist reversed this effect; this suggested that empagliflozin may, at least partly, decrease CD36 by modulating PPARγ. In conclusion, empagliflozin can ameliorate FFA-induced renal tubular injury via the PPARγ/CD36 pathway. MDPI 2021-11-17 /pmc/articles/PMC8621539/ /pubmed/34830289 http://dx.doi.org/10.3390/ijms222212408 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Chiang-Chi Chou, Chia-An Chen, Wei-Yu Yang, Jenq-Lin Lee, Wen-Chin Chen, Jin-Bor Lee, Chien-Te Li, Lung-Chih Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice |
title | Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice |
title_full | Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice |
title_fullStr | Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice |
title_full_unstemmed | Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice |
title_short | Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice |
title_sort | empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the pparγ/cd36 pathway in obese mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621539/ https://www.ncbi.nlm.nih.gov/pubmed/34830289 http://dx.doi.org/10.3390/ijms222212408 |
work_keys_str_mv | AT huangchiangchi empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT chouchiaan empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT chenweiyu empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT yangjenqlin empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT leewenchin empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT chenjinbor empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT leechiente empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice AT lilungchih empagliflozinamelioratesfreefattyacidinducedlipotoxicityinrenalproximaltubularcellsviatheppargcd36pathwayinobesemice |